Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Sanofi Fined for ‘Smear Campaign’ Against Generic Plavix

By Pharmaceutical Processing | May 14, 2013

France’s antitrust authority on Tuesday fined Sanofi 40.6 million euros ($52.6 million) for a “smear campaign” designed to limit sales of generic versions of Plavix. The ruling on the drug, which last year generated global sales of nearly 2.1 billion euros ($2.7 billion), follows a complaint by Teva.

The competition authority claimed that Sanofi’s sales force cast doubt on the efficacy of generic versions of Plavix in conversations with doctors and pharmacists in 2009 and 2010. The drugmaker also urged doctors to write on prescriptions that the generic version was not substitutable for the branded product, and pushed for use of its own generic version rather than those from other companies.

According to the competition regulator, France’s national health system paid 625 million euros ($810 million) for the use of Plavix in 2008, the most of any medicine. Sanofi said that it disagrees with the ruling and is “reviewing all the points to prepare an appeal before the Paris appeals court.”

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE